Lactobacillus rhamnosus GG and HbA1c in middle age and older adults without type 2 diabetes mellitus: A preliminary randomized study.
- 2020-09
- Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14(5)
- PubMed: 32570015
- DOI: 10.1016/j.dsx.2020.05.034
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Sample size
- n = 190
- Population
- Healthy middle-aged and older adults
- Methods
- Randomized Controlled Trial
Abstract
Background and aims: Probiotic supplementation improves glycemic control in persons with diabetes and the current study examined whether these benefits extend to healthy individuals.
Methods: The current study was a 90-day placebo-controlled, double-blind, randomized clinical trial of Lactobacillus rhamnosus GG in healthy middle-aged and older adults. Fasting blood glucose and HbA1c were quantified at baseline and follow up.
Results: ANCOVA controlling for baseline values showed group differences in follow up HbA1c [F (1,90) = 8.44, p = 0.005]; HbA1c values increased in the placebo group, though remained stable in the probiotic group.
Conclusions: If replicated, Lactobacillus rhamnosus GG may protect against changes in glycemic control.
Keywords: Diabetes mellitus; Gut microbiota; Lactobacillus; Probiotic.
Research Insights
| Supplement | Dose | Health Outcome | Effect Type | Effect Size | Source |
|---|